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Abstract
Background: Estimating costs is essential to the economic analysis of health care programs. Health care costs are
often captured from administrative databases or by patient report. Administrative records only provide a partial
representation of health care costs and have additional limitations. Patient-completed questionnaires may allow a
broader representation of health care costs; however the validity and feasibility of such methods have not been
firmly established. This study was conducted to assess the validity and feasibility of using a patient-completed
questionnaire to capture health care use and costs for patients with osteoarthritis, and to compare the research
costs of the data-capture methods.
Methods: We designed a patient questionnaire and applied it in a clinical trial. We captured equivalent data from
four administrative databases. We evaluated aspects of the questionnaire’s validity using sensitivity and specificity,
Lin’s concordance correlation coefficient (rc), and Bland-Altman comparisons.
Results: The questionnaire’s response rate was 89%. Acceptable sensitivity and specificity levels were found for all
types of health care use. The numbers of visits and the majority of medications reported by patients were in
agreement with the database-derived estimates (rc > 0.40). Total cost estimates from the questionnaire agreed
with those from the databases. Patient-reported co-payments agreed with administrative records with respect to
GP office transactions, but not pharmaceutical co-payments. Research costs for the questionnaire-based method
were less than one-third of the costs for the databases method.
Conclusion: A patient-completed questionnaire is feasible for capturing health care use and costs for patients with
osteoarthritis, and data collected using it mostly agree with administrative databases. Caution should be exercised
when applying unit costs and collecting co-payment data.
Background
The estimation of costs is an essential component in
economic analyses of health care. Such estimations
involve identifying the relevant cost items, determining
the quantities of resources used, and assigning unit
costs (also known as price weights) to the cost items
[1]. Once relevant costs are identified, the types and
quantities of resources used can be obtained by acces-
sing information from health care providers, funders, or
patients [2].
Providers’ administrative databases and medical
records are potentially rich sources of data. Auditing
medical records has been considered the gold standard
for identifying and quantifying health care use, but this
approach has limitations [3,4]. Usually only a partial
representation of direct costs is captured per provider,
multiple providers must be approached for each patient,
and cooperation from administrative staff is required
[4,5]. Providers may restrict access to medical records
due to privacy or security concerns, and computer data-
bases may be designed to track patients’ billing rather
than their medical histories [4]. Medical reports may
also contain inaccuracies; Jordan et al. suggests that
repeat consultations and consultations for multiple con-
ditions may not be accurately recorded [6]. Orrico
* Correspondence: daniel-pinto@northwestern.edu
1Centre for Physiotherapy Research, School of Physiotherapy, University of
Otago, Dunedin 9054, New Zealand
Full list of author information is available at the end of the article
Pinto et al. BMC Medical Research Methodology 2011, 11:45
http://www.biomedcentral.com/1471-2288/11/45
© 2011 Pinto et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.reviewed discrepancies between patient self-reporting
and medical records with respect to outpatient medica-
tion use and found that discrepancies arose from medi-
cal system errors in 49% of such instances [7].
When estimating costs, using the societal perspective
allows for the broadest capture of costs [8]. It is also
generally the ‘gold standard’ with regards capturing cost
transfers, opportunity costs, and comparability of results
[9]. In many situations patients must be asked about
their health care use, expenses and other consequences,
because administrative databases cannot capture all such
information [10]. Methods for collecting patient-
reported data include cost diaries, questionnaires, and
patient interviews. These measures can be differentiated
by their use of prospective versus retrospective report-
ing. Diaries are regarded as prospective instruments
because a patient has the diary prior to the health visit
and typically uses very small recall periods to record
health care use, which minimizes recall bias [11].
Though the health diary has clear advantages when cap-
turing data about daily symptoms, the superiority of this
method for capturing health care use is less clear [11].
Major disadvantages of diaries include the burden on
patients, complexity of data processing and analysis,
exclusion of patients who are functionally illiterate,
inability of researchers to immediately probe for addi-
tional data, high levels of item-level missing data, and
dependence on participants’ motivation to record their
data [11,12]. Retrospective methods for capturing health
data include questionnaires and patient interviews. Like
diaries, these methods can provide researchers with
ample detail and information unavailable from provider
databases; however, because they are retrospective they
are susceptible to recall bias. The risk of recall bias can
be reduced by carefully designing the questionnaire or
interview instrument [13].
It is important before applying a self-report instru-
ment in an economic study to assess its accuracy [14].
In this study we describe the development and testing
of the Osteoarthritis Cost and Consequences Question-
naire (OCC-Q) for capturing health care use and costs
in patients with osteoarthritis. Our primary objectives
were to assess the validity and feasibility, in a clinical
trial setting, of using the OCC-Q compared with using
administrative databases and to compare the research
costs of these two data-capture methods.
The New Zealand health system context
New Zealand’s health system is a public system, mainly
funded from taxation. Most hospitals are publicly owned
and are administered by 21 District Health Boards
(DHBs) throughout the country. Along with community
guidance, primary health care is managed by DHBs and
Primary Health Organisations (PHOs), whose job it is to
provide primary health care services to enrolled patients.
P H O si n c l u d em u l t i p l ep r i m a r yh e a l t hc a r ep r o v i d e r s
including general practitioners (GPs), nurses, pharma-
cists, and physiotherapists [15]. The government funds
PHOs via DHBs through weighted capitation where
funding rates increase based on the expected number of
primary health visits per annum and the specified range
of health care needs of the enrolled patient [16-18].
Individuals must register with PHOs in order to receive
subsidised primary care [15]. Services provided by medi-
cal specialists and allied health workers are mostly free
to patients if the services are provided via DHBs; other-
wise patients usually incur the full price as out-of-
pocket costs [17]. Publicly-funded pharmaceuticals are
purchased by New Zealand’s Pharmaceutical Manage-
ment Agency (PHARMAC), and most physician-pre-
scribed pharmaceuticals are available to patients for a $3
co-payment.
Methods
Data intended for performing a cost-utility analysis were
collected as part of the Management of Osteoarthritis
(MOA) trial - a randomized controlled trial investigating
the value of physiotherapy in addition to usual care for
patients with hip or knee osteoarthritis (OA) undertaken
in Dunedin, New Zealand [19]. Participants were
recruited at the Dunedin Hospital Orthopaedic Clinic
and from GP clinics in the local metropolitan area.
Research nurses screened potential participants by
reviewing patients’ charts and interviewing them by tele-
phone. Patients were included in the trial if they met
clinical criteria for hip or knee OA according to the
American College of Rheumatology [20,21]. They were
excluded if they had any of the following: a joint repla-
cement in the affected joint; any surgical procedure of
the lower limbs in the previous 6 months; rheumatoid
arthritis; initiation of an opiate analgesic, corticosteroid,
or analgesic injection within the previous 30 days;
uncontrolled hypertension or moderate-to-high risk of
cardiac complications during exercise; other physical
impairments precluding safe participation in the trial; an
inability to comprehend instructions; and an inability to
complete the trial [19]. Participants gave their informed
consent to allow their medical records to be reviewed
and compared, and ethical approval was granted by the
Lower South Regional Ethics Committee.
Questionnaire development
The OCC-Q (the Osteoarthritis Cost and Consequences
Questionnaire) was designed to capture health care use,
patient co-payments, and other out-of-pocket costs
related to hip or knee OA over the preceding three-
month period. We developed the questionnaire based
on existing tools and recommendations [22-24] with
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clinical pharmacy and physiotherapy. Many of the ques-
tionnaire sections were modeled after the questionnaire
reported by Cochrane et al [22]. Modifications included
the standardization of the recall timeframe to three-
months for the majority of health care use and increased
detail of resource utilization domains. Health care ser-
vices and expenses with the potential to contribute sig-
nificantly to OA-related costs such as OA-related
medications and inpatient care were listed in detail to
improve participants’ recall and decrease the effect of
fatigue on recall [13,23]. The questionnaire was assessed
to ensure that resource utilization domains, recom-
mended for the assessment of costs in musculoskeletal
diseases, were being captured [24]. The questionnaire
was pilot-tested on patients with OA to check the clarity
of its questions and its capacity to capture OA-related
costs and consequences.
At the three-month follow-up point (April 2008 to
December 2009), a cover letter and questionnaire with a
return postage-paid envelope were sent to the first 56
participants in the MOA trial. The cover letter explained
our interest in the participant’s health care use since the
start of the MOA trial, with each participant’s trial start
date mentioned to improve recall. The questionnaire
asked the participant to recall his or her visits to GPs,
public and private hospitals, and any community ser-
vices received. It also asked about any time off work,
co-payments or out-of-pocket costs related to OA over
the three-month period, and use of OA-related medica-
tions during the previous week. Participants were invited
in the cover letter to ring the contact phone number
provided if they had any questions. The cover letter also
mentioned that a researcher would phone to conduct a
brief interview after the questionnaire was returned. If
questionnaires were not received by one week following
the mailing, participants were phoned and reminded
about the questionnaire; and if necessary, this was
repeated after two weeks.
The first author (DP) followed-up the returned ques-
tionnaires with a 5-10 minute phone call to each
respondent to review his or her responses, in particular,
with respect to the study’s definition of OA-related
health care. Respondents were encouraged to define a
GP or hospital visit as OA-related if it was a follow-up
for their hip or knee complaints, if a significant part of
the visit was devoted to their hip or knee complaints, or
if the doctor renewed their OA-related prescriptions.
OA-related medications were specified as a pre-defined
list of analgesics, anti-ulcerants, and psychotropics in
the questionnaire. Interview techniques including
prompting, and relating health care consultations to a
consequence, such as a prescription or referral, were
used to improve recall [6,13].
Administrative databases
Covering the same three-month period as the question-
naire, the lead author (DP) collected data on each parti-
cipant’s use of GP services, hospital services, and
medication use from administrative databases. GP con-
tacts, which included visits to the GP or practice nurse
and any contact for a renewal of OA-related medica-
tions, were captured by: (1) performing electronic data-
base queries in GP offices using the Medtech patient
management system (Medtech Global Ltd); and (2) by
manually searching medical records at 17 GP offices in
the Dunedin metropolitan area. Patient co-payments
were captured from the GP record. Three medical
records from one additional GP office were obtained via
a telephone interview with the GP. A query of the local
hospital’s medical records captured data on each partici-
pant’s use of OA-related inpatient and outpatient ser-
vices by the sole public provider, the Otago DHB. Data
on all medical imaging services were captured from the
EasyRIS database (Philips Medical Systems) operated by
the Otago DHB. A query of the New Zealand Health
Information Service (NZHIS) database captured data on
dispensed medications funded by PHARMAC (New
Zealand’s Pharmaceutical Management Agency). The
same definition of OA-related health care as expressed
above was used to screen the administrative databases;
likewise, only OA-related medications listed in the ques-
tionnaire were included in the NZHIS query. Medication
costs, quantities dispensed, and expected patient contri-
butions were captured from the NZHIS query.
Price weights
All costs in this study are reported in 2009 New Zealand
dollars (NZD); the conversion rate to US dollars (USD)
at 2009 purchasing power parity is $1 NZD=$0.63 USD.
All costs are exclusive of government Goods and Ser-
vices Tax (GST) in order to represent costs to society.
We applied the price weights reported in Table 1 to the
questionnaire results. Participants were asked to report
out-of-pocket costs for health care including GP con-
tacts and pharmaceutical prescriptions to enable the
assessment of agreement between the methods of
reporting with respect to out-of-pocket costs. For sim-
plicity, hereinafter we refer to all patient out-of-pocket
costs as co-payments. The NZHIS query reported the
government subsidy for each relevant medication and an
expected co-payment. To generate an estimate of a
comparable subsidy using the OCC-Q, self-reported
daily quantities of medications were extrapolated to
three-month quantities, and then multiplied by the
appropriate medication unit cost as reported in the New
Zealand Pharmaceutical Schedule [25]. Consistent with
prescribing of PHARMAC-funded medications in New
Zealand, all prescriptions were assumed to provide three
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which are prescribed for just one month [25].
Item-level missing values
Missing data were imputed using ICE (imputation using
chained equations) in Stata version 11.1 (Stata, College
Station, Tex., USA) [26] for each missing item of
resource use versus total cost. ICE was chosen because
it provides support for categorical missing values, using
logistic regression for binary variables and multinomial
or ordered logistic regression for categorical variables
[27].
Data analysis
We measured the agreement between the estimates of
each participant’s health care use as captured by the
OCC-Q and the administrative databases. The adminis-
trative database records served as the gold standard to
compute sensitivity and specificity. Sensitivity is the pro-
portion of participants who reported health care use
when the administrative database indicates that such
services were used. Specificity is the proportion of parti-
cipants who reported no health care use when the data-
base record indicates that no services were used.
Sensitivity and specificity were calculated to assess
agreement for the dichotomous (yes/no) reporting of
health care use with respect to GP contacts, individual
medication categories, inpatient services, outpatient
orthopaedic visits, outpatient rheumatology visits, and
medical imaging procedures.
To assess the level of agreement between the reported
quantities and costs of health care use, we used Lin’s
concordance correlation coefficient (rc)w h i c hm e a s u r e s
agreement between two continuous variables taking into
account systematic bias [28]. Ranging between 1 (perfect
agreement) and -1 (perfect inverse agreement), rc repre-
sents the extent to which the compared data deviate sig-
nificantly from perfect concordance [29]. A significant
advantage for our analysis is that rc can be applied to
data from non-normal distributions, such as cost data.
Values for rc were interpreted according to these levels
of agreement: ‘poor’ = 0.00-0.40, ‘fair’ = 0.40-0.59, ‘good’
= 0.60-0.74 and ‘excellent’ = 0.75-1.00 [30]. A threshold
of rc = 0.40 was used to determine whether levels of
agreement had clinical/practical significance [30]. We
also reported mean differences; 95% confidence intervals
and 95% limits of agreement were reported to assess
systematic bias and to identify random variation
between individual measurements respectively [31,32].
With respect to missing data, we imputed 5 datasets
to reflect the uncertainty surrounding the imputed
values. Where mean estimates were reported, we used
the estimate of the mean across the 5 imputed datasets.
We performed rc, Bland-Altman comparisons, and 95%
limits of agreement using each imputed dataset. The
results of all comparisons fell within the confidence
intervals calculated using the other four imputed data-
sets, therefore we reported the estimates using the first
imputed dataset only. We used Stata version 11.1 for
data analysis.
Results
Fifty of the first 56 participants in the MOA trial who
were invited to participate in the present study agreed
(response rate = 89%). Their average age was 70.0 years
(SD ± 7.9 years), 97% identified themselves as being of
Pakeha/New Zealand European ethnicity, 58% were
female, 62% had a primary complaint of knee OA (38%
Table 1 Price weights for the estimation of costs*
Cost items Price weight Source
General practitioner (GP) services
GP visits $62 Average private fee from 10 Dunedin (New Zealand)
GP offices
Prescription $12
Medications
Analgesics Price weight based on New Zealand Pharmaceutical Schedule
Anti-ulcerants medication dosage and number
Psychotropics of tablets/capsules issued
Hospital costs
Inpatient services $3,983.33 multiplied by inpatient
service case weights
New Zealand’s case-mix framework for publically funded
hospitals for fiscal year 2008/09: WIESNZ08
Emergency visits $322 Hospital’s volume schedule from funder
Outpatient orthopaedic visits $158
Rheumatologist visits $210
Medical imaging $55 multiplied by relative value
unit of procedure
Imaging contract between the Accident Compensation
Corporation and the hospital
*All monetary values are in 2009 New Zealand dollars (NZD); the conversion rate to US dollars (USD) at 2009 purchasing power parity is $1 NZD = $0.63 USD.
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years or more, and 68% had at least one co-morbidity.
Table 2 reports the summary statistics including inter-
quartile range and mean for cost comparisons. The
patient interview took an average of 8 minutes. Only
1.6% of the data were missing.
Validity
Agreement for dichotomous reporting
As reported in Table 3, agreement for the dichotomous
reporting of health care use varied. Generally, a trade-
off was apparent between values for sensitivity and spe-
cificity. The self-reporting of GP contacts, paracetamol,
NSAIDs, and rheumatology had higher levels of sensitiv-
ity (93%-100%) than specificity (63%-100%). The self-
reporting of opiates, paracetamol and opiate-combina-
tion medications, anti-ulcerants and medical imaging
had higher specificity (93%-100%) than sensitivity (44%-
80%).
Agreement for quantity reporting
Only GP contacts and medications were recorded in
sufficient quantities for their quantity data to be ana-
lysed using Lin’s rc and Bland-Altman comparisons. As
reported in Tables 3 &4, participants recounted fewer
GP contacts and more medications using the OCC-Q;
however the mean differences between assessment
methods were small: 0.06 and -0.22 respectively. Con-
cordance levels were fair (rc = 0.41) for the number of
GP contacts and good (rc = 0.63) for the number of
medications reported.
Agreement for reporting of costs
Table 5 compares cost estimates derived from the OCC-
Q and administrative databases respectively. Cost esti-
mates for GP services and the majority of medication
subsidies exhibited acceptable levels of agreement (rc ≥
0.40). The majority of co-payments for medications
showed poor agreement (rc < 0.40), as did total medica-
tion costs. All hospital services resulted in acceptable
agreement except for orthopaedics (rc = 0.316).
Research costs
Table 6 summarizes the research costs incurred for each
data-collection method. The cost of the questionnaire-
based method was less than one-third of the cost of
extracting the same data from administrative databases,
enabling a potential savings of $1,940 NZD for our
sample.
Discussion
We found that using a patient-completed questionnaire
was a feasible and valid method of capturing health care
use and costs for patients with OA compared with
accessing administrative databases. First, with respect to
the questionnaire’s feasibility and research costs,
response rates were high (89%); though a minority of
participants needed up to two telephone calls in order
to return the questionnaire. Item-level missing data
were minimal (1.6%) and research costs were consider-
ably lower than relying on administrative databases. A
review by Verbrugge [11] showed a range of 7-33% of
item-level missing data for diaries. This metric was not
reported by Goossens et al. [10]; however they reported
that only 68% of diaries were returned.
As for previous studies [3,4,10,33,34], we found high
levels of agreement between the data-collection methods
for salient, high-cost health services such as hospitaliza-
tions and emergency visits. Participants more accurately
reported their non-use (specificity) than use of health
care (sensitivity). This likely reflects the three-month
time horizon, which for most participants resulted in a
Table 2 Summary statistics of cost comparisons between the OCC-Q and the administrative database results*
Minimum 0.25 Median Mean 0.75 Maximum
General practitioner costs
OCC-Q 0 62 62 80.08 124 248
General practitioner database 0 62 62 71.80 86 310
Medication costs
OCC-Q† 0 9.91 26.51 34.30 48.94 210.12
New Zealand Health Information System 0 3.22 21.22 36.79 50.8 305.14
Hospital costs
OCC-Q 0 0 37.74 393.53 233 14,599.83
Otago District Health Board query 0 0 0 376.87 157.52 14,599.83
Total costs
OCC-Q† 0 88.49 219.99 516.52 326.63 15,141.16
Databases 0 72.59 144.78 485.46 243.40 15,029.33
*All monetary values are in 2009 New Zealand dollars (NZD); the conversion rate to US dollars (USD) at 2009 purchasing power parity is $1 NZD = $0.63 USD.
†The first imputed dataset was used for descriptive statistics.
Abbreviations: OCC-Q, Osteoarthritis Cost and Consequences Questionnaire.
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administrative databases
Health care Sensitivity Specificity
General practitioner
GP contacts YES (PT) NO (PT)
YES (DB) 38 3 93% 56%
NO (DB) 4 5
Medications
Paracetamol YES (PT) NO (PT)
YES (DB) 23 0 100% 59%
NO (DB) 11 16
Opiates YES (PT) NO (PT)
YES (DB) 4 5 44% 93%
NO (DB) 3 38
Paracetamol & opiates* YES (PT) NO (PT)
YES (DB) 4 5 44% 93%
NO (DB) 3 38
NSAIDs YES (PT) NO (PT)
YES (DB) 17 1 94% 84%
NO (DB) 5 27
Pantoprazole YES (PT) NO (PT)
YES (DB) 2 1 67% 100%
NO (DB) 0 47
Omeprazole YES (PT) NO (PT)
YES (DB) 12 3 80% 91%
NO (DB) 3 32
Amitriptyline YES (PT) NO (PT)
YES (DB) 2 1 67% 98%
NO (DB) 1 46
Hospital services
Emergency visits YES (PT) NO (PT)
YES (DB) 2 0 100% 100%
NO (DB) 0 48
OA-related inpatient events YES (PT) NO (PT)
YES (DB) 2 0 100% 100%
NO (DB) 0 48
Orthopaedics YES (PT) NO (PT)
YES (DB) 7 3 70% 85%
NO (DB) 6 34
Rheumatology YES (PT) NO (PT)
YES (DB) 2 0 100% 98%
NO (DB) 1 47
Medical imaging services† YES (PT) NO (PT)
YES (DB) 10 4 71% 81%
NO (DB) 7 29
*Combination drug
†n=4 8
Abbreviations: GP, general practitioner; DB, database; PT, patient; Opiates=codeine, DHC continus; NSAIDs, non-steroidal anti-inflammatory drug = diclofenac,
voltaren, ibuprofen, naproxen
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cetamol, and NSAIDs, sensitivity was higher than speci-
ficity (Table 2). The lower specificity levels for GP
contacts may be the result of recall bias. Given the short
timeframe of our study, it is unlikely this discrepancy
reflects participants forgetting their visits. Rather, it may
be the result of ‘telescoping’ (or ‘reverse telescoping’)
which occurs when a person includes (or ‘telescopes’)
health care used outside of the study time period, or
when health care from within the study time period is
‘reverse telescoped’ out [13]. Telescoping does not result
in a consistent bias [13]. The lower specificity of parace-
tamol and NSAIDs may be associated with the lower
actual use of these medications (often taken on an ‘as
needed’ basis) than as prescribed. In other words, a par-
ticipant may have accurately reported use of a medica-
tion, but because this was less than prescribed, no new
dispensing of the medication was required within the
three-month time horizon leaving no record in the
database.
We were able to only analyse quantity data for GP vis-
its and the number of medications used. Utilization was
too low to assess quantity data for the other health care
included in our study. Levels of agreement between the
assessment methods were acceptable (rc > 0.40) for the
number of GP visits and total number of medications
used. We also compared cost estimates using Lin’sc o n -
cordance correlation coefficient (rc) and Bland-Altman
comparisons. Societal costs and co-payments associated
with GP visits were in agreement with database results
(rc = 0.502). For the majority of medication subsidies,
the cost estimates from the OCC-Q and NZHIS agreed.
The questionnaire underestimated paracetamol subsidy
by an average of $0.58 per person (2009 NZD) and
overestimated patient co-payment by $12.34 per person.
We believe this to be the result of some participants
being prescribed the medication by their GP but, instead
of filling the prescription at a pharmacy, they chose to
purchase the medication over-the-counter.
The self-reporting of omeprazole subsidy disagreed
with the NZHIS results (rc = 0.13) despite dichotomous
reporting of omeprazole use corresponding to sensitivity
and specificity levels of 80% and 91% respectively. This
discrepancy appeared to be related to the reimburse-
ment of a more expensive brand-named drug, Losec, in
the NZHIS record. We did not account for the reimbur-
sement of Losec in the questionnaire-based estimates
because it was not included in the pharmaceutical sche-
dule. We can only guess why Losec was reimbursed by
the government agency (PHARMAC) despite it not
being on the pharmaceutical schedule. Perhaps it was
the result of a rebate agreement with the manufacturer
o rap u r c h a s eb yt h eO t a g oD H B .T h er e m o v a lo fo m e -
prazole from the total medication cost increased the
concordance correlation coefficient to levels well beyond
the threshold of clinical/practical agreement (data not
reported). This illustrates the importance of knowing
which unit costs to use when estimating costs. It also
shows how reasonable attempts at using the appropriate
unit cost may not capture costs that are not reported in
the public domain.
For most medications, there were poor agreements for
co-payments, though mean differences were low
(< $4.26 for all but paracetamol). This was likely due to
a combination of participants not accurately recalling
their co-payments and errors in the expected contribu-
tion reported by NZHIS. This was a particularly difficult
task for participants because they often combined store
purchases with medication co-payments when at the
pharmacy. For this reason, we recommend that analysts
use caution when capturing co-payments for particular
cost items. An understanding of the environment in
which co-payments are made is important. For example,
an option other than self-report may be required for
studies set in countries where medication co-payments
take place in a pharmacy in which purchases unrelated
to health care can be made. If available, options such as
average medication co-payments may be applied. How-
ever, considering the low impact of the co-payment on
the cost of total health care use, it may not be worth-
while investing a large amount of analyst resources to
increase the accuracy of this particular cost [1].
Our results compare favourably with other studies that
assessed agreement between patient report and adminis-
trative records [3,34]. We compared our results with
two studies that reported data in cross tables, which
allowed us to calculate sensitivity and specificity from
their findings. Data reported by Ruof et al. indicated
excellent sensitivity for physician visits (100%) [34]. This
physician visit category was a general measure that
Table 4 Agreement between the OCC-Q and the databases for the reported quantity of health care used
OCC-Q
Mean ± SD
Databases
Mean ± SD
rc* Mean difference
(95% CI)†
95% limits of
agreement
GP contacts 1.3 ± 1.0 1.4 ± 1.2 0.41 0.06 (-0.3, 0.4) -2.34 to 2.46
Total number of medications 1.8 ± 1.2 1.6 ± 1.2 0.63 -0.22 (-0.50, 0.07) -2.25 to 1.8
*rc = Lin’s concordance correlation coefficient.
†95% CI assumes a normal distribution.
Abbreviations: OCC-Q, Osteoarthritis Cost and Consequences Questionnaire; GP, general practitioner; SD, standard deviation; CI, confidence interval.
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databases*†
OCC-Q ($)
Mean ± SD
Databases ($)
Mean ± SD
rc‡ Mean difference ($)
(95% CI)§
95% limits of
agreement ($)||
GP services
Co-payments 37.59 ± 29.46 29.62 ± 29.53 0.502 -7.97 (-16.39, 0.46) -67.28 to 51.35
Societal cost 79.84 ± 60.84 67.08 ± 61.38 0.502 -14.24 (-30.92, 2.44) -131.63 to 103.15
Medications
Subsidy
Paracetamol n = 49 2.96 ± 2.90 3.57 ± 6.36 0.358 0.60 (-1.00, 2.21) -10.58 to 11.78
Imputed (n = 50) 3.02 ± 2.93 3.50 ± 6.32 0.360 0.58 (-1.02, 2.13) -10.53 to 11.64
Opiates 1.89 ± 6.36 3.83 ± 11.54 0.645 1.94 (-0.24, 4.13) -13.45 to 17.33
Paracetamol & opiates 3.20 ± 7.16 2.84 ± 7.50 0.807 -0.36 (-1.66, 0.93) -9.48 to 8.75
NSAID n = 45 4.12 ± 7.05 3.66 ± 7.45 0.876 -0.44 (-1.52, 0.64) -7.63 to 6.74
Imputed (n = 50) 4.74 ± 7.60 3.59 ± 7.11 0.789 -1.10 (-2.42, 0.22) -10.40 to 8.19
Pantoprazole 0.43 ± 2.13 0.67 ± 2.74 0.716 0.24 (-0.28, 0.77) -3.44 to 3.92
Omeprazole n = 45 2.89 ± 6.34 17.30 ± 50.56 0.140 14.41 (0.30, 28.51) -77.62 to 106.44
Imputed (n = 50) 3.56 ± 6.35 19.03 ± 49.32 0.137 15.45 (2.42, 28.48) -76.24 to 107.15
Amitriptyline 0.45 ± 1.72 0.30 ± 1.27 0.225 -0.15 (-0.68, 0.36) -3.91 to 3.61
Co-payment
Paracetamol n = 40 5.08 ± 16.52 0.83 ± 1.36 -0.006 -4.25 (-9.57, 1.07) -36.79 to 28.59
Imputed (n = 50) 8.88 ± 36.86 0.66 ± 1.26 -0.008 -12.34 (-22.55, -2.13) -84.19 to 59.51
Opiates 0.30 ± 0.91 0.40 ± 1.18 0.716 0.10 (-1.24, 0.32) -1.48 to 1.68
Paracetamol & opiates¶ 1.39 ± 4.05 0.48 ± 1.85 0.168 -0.91 (-2.06, 0.24) -9.00 to 7.18
NSAID n = 44 1.23 ± 4.98 0.93 ± 1.66 0.151 -0.30 (-1.77, 1.18) -9.76 to 9.21
Imputed (n = 50) 1.18 ± 4.68 0.88 ± 1.61 0.148 -0.28 (-1.58, 1.02) -9.41 to 8.85
Pantoprazole 0.12 ± 0.59 0.12 ± 0.59 1.00 0.00 (0.00, 0.00) 0.00 to 0.00
Omeprazole n = 44 0.82 ± 2.45 0.47 ± 1.11 0.176 -0.34 (-1.08, 0.40) -5.22 to 4.54
Imputed (n = 50) 1.06 ± 3.31 0.42 ± 1.05 0.143 -0.54 (-1.22, 0.14) -5.34 to 4.26
Amitriptyline 0.18 ± 0.72 0.06 ± 0.42 -0.031 -0.12 (-0.36, 0.12) -1.81 to 1.58
Total medication cost n = 31 24.36 ± 25.04 41.00 ± 59.76 0.144 -16.63 (-38.49, 5.23) -135.82 to 102.56
Imputed (n = 50) 30.40 ± 39.83 36.79 ± 52.90 0.152 5.70 (-11.51, 22.91) -115.41 to 126.81
Hospital-based services
Emergency visits 13.36 ± 66.11 13.36 ± 66.11 1.00 0.00 0.00 to 0.00
OA-related inpatient events 292.00 ± 2064.73 292.00 ± 2064.73 1.00 0.00 0.00 to 0.00
Orthopaedics 50.41 ± 80.76 37.80 ± 81.51 0.316 -9.45 (-35.68, 16.78) -194.03 to 175.13
Rheumatology 16.76 ± 71.33 12.57 ± 65.71 0.701 -4.19 (-12.61, 4.23) -63.45 to 55.07
Medical imaging n = 48 24.15 ± 35.57 21.13 ± 34.23 0.488 -3.02 (-12.67, 6.63) -70.94 to 64.90
Total hospital costs 393.53 ± 2054.51 376.87 ± 2057.66 0.998 -16.66 (-48.01, 14.68) -237.25 to 203.93
Total health care cost n = 31 209.27 ± 167.95 192.51 ± 183.74 0.606 -16.75 (-73.84, 40.33) -328.01 to 294.51
Imputed (n = 50) 513.20 ± 2132.22 485.46 ± 2105.69 0.997 -34.05 (-76.65, 8.55) -333.83 to 265.73
*All monetary values are in 2009 New Zealand dollars (NZD), with a conversion rate to US dollars (USD) at 2009 purchasing power parity of $1 NZD = $0.63 USD.
†OCC-Q datasets are complete (n = 50) unless indicated otherwise (Database records have no missing values), n < 50 = complete case analysis for OCC-Q with
the same cases dropped from the Database, Imputed n = 50 indicates the mean ± SD for OCC-Q values are estimated from 5 imputed datasets combined; rc,
mean difference 95% CI, and 95% limits of agreement are estimated using the first imputed dataset.
‡rc = Lin’s concordance correlation coefficient
§95% CI assumes a normal distribution.
||95% limits of agreement.
¶Combination product.
Abbreviations: OCC-Q, Osteoarthritis Cost and Consequences Questionnaire; GP, general practitioner; SD, standard deviation; CI, confidence interval; NSAID, non-
steroidal anti-inflammatory drug: diclofenac, voltaren, ibuprofen, naproxen; Opiates: codeine, DHC continus.
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Page 8 of 11included GPs and specialists. Ruof et al. grouped physi-
cians to increase agreement; however applying costs to
such a general measure would be difficult. Disaggregated
physician visits were not included in the cross tables but
the authors indicated that kappa values were < 0.2 (poor
agreement) for all physician categories [34]. With
respect to GP visits, data reported by Raiana et al. indi-
cated sensitivity levels (95%) similar to our study (93%),
but lower specificity levels (20%) suggesting that partici-
pants in their study were less able to accurately recall a
non-attendance than our participants [3]. Our results
were stronger for the quantity of GP visits reported
when compared with Raiana et al. (intra-class correla-
tion coefficient of 0.34), though their population had a
greater proportion of demographic factors associated
with poorer agreement [3]. Ruof et al. reported high
sensitivity levels (> 90%) for the majority of medications
assessed [34]. This was higher than for our study, which
m a yh a v eb e e nd u et od i f f e r e n c e si nt h ep o p u l a t i o n s
studied. Ruof et al. studied patients with rheumatoid
arthritis, who typically receive intensive, medication-
based treatment that slows disease progression [23]. The
primary use of medication as a disease-modifying treat-
ment may increase a patient’s ability to recall use of that
particular health care item [13].
Two characteristics of our study may have increased
the complexity of our data collection and analysis. The
first is the use of an imperfect gold standard. Adminis-
trative databases have been shown to have errors [6,7].
Having an imperfect gold standard complicates the
assessment of accuracy, often resulting in an upward or
downward bias of the accuracy estimate [35]. Reitsma et
al. review methods to correct the gold standard which
include adjusting it by percentages of error that are
found in the literature or that may be considered plausi-
ble [35]. However, little evidence exists to guide the cor-
rection of cost data from administrative databases. An
example from our study illustrates imperfection of our
gold standard with respect to the reporting of OA-
related inpatient services. One total knee replacement
was recorded on the patient questionnaire, but not in
the administrative database. When manually searching
the hospital records for this participant we found opera-
tive notes indicating that a knee replacement had indeed
been performed during the study period. In addition to
decreasing our estimate of accuracy for the reporting of
OA-related inpatient events, the removal of this proce-
dure from total costs of health care services would have
substantially affected our results.
The second characteristic that may have complicated
data collection was the use of OA-related costs. There is
a possibility that patients and researchers do not agree
on what ‘OA-related’ means. We attempted to minimize
this discrepancy by using firm definitions for
Table 6 Incremental research costs associated with the methods used to collect health care use and cost data*
OCC-Q GP records Hospital
database
Medical imaging
records
New Zealand Health
Information System
Combined
databases
$$ $ $ $ $
Materials (× 50) 170.04 0 0 0 0 0
￿ 13 page questionnaire
￿ Cover letter
￿ 1 Legal envelope
￿ 1 Letter envelope
￿ Return postage
Printing, assembling, mailing (time)† 83.60 0 0 0 0 0
Telephone follow-up† 42.85 0 1.67 1.67 3.55 6.89
Emails† 0 0 1.67 1.67 1.67 5.01
Query design 0 0 784.58‡ 150.47‡ 141.22‡ 1076.27
Data collection (patient level) 217.78† 262.09† 232.73§ 135.23§ 0 630.05
Questionnaire scanning† 51.21 0 0 0 0 0
Data normalization† 334.40 250.80 125.4 41.80 167.20 585.20
Travel reimbursement 0 176.80¶ 0 0 0 176.80
Query building/reporting fee 0 160.00 0 0 200.00 360.00
Total cost 899.88 849.69 1146.01 330.84 513.64 2840.22
*All monetary values are in 2009 New Zealand dollars (NZD); the conversion rate to US dollars (USD) at 2009 purchasing power parity is $1 NZD = $0.63 USD.
Abbreviations: OCC-Q, Osteoarthritis Cost and Consequences Questionnaire; GP, general practitioner.
†Time valued at research assistant hourly rate of $20.90.
‡Hospital database query design.
§Hospital database: 7 hours of computer analyst time ($32.50), 0.25 hours research assistant time ($20.90), radiology database: 4 hours computer analyst time,
0.25 hours research assistant time.
¶Travel reimbursement was $0.85/Km.
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Page 9 of 11determining which services constitute OA-related health
care. Though we used definitions for OA-related health
care use, we acknowledge that medicine is multifactorial
and that there is little evidence supporting the use of
definitions to identify what is and is not disease-related
[36]. The decision to use OA-related costs was made in
order to reduce variability of our cost estimates by limit-
ing costs to those related to OA. The results of our
study may give researchers who are interested in ana-
lyses of ‘OA-related’ disease support in the application
of a definition that resulted in high levels of agreement
between patients filling out a questionnaire and
researchers applying the definition against administrative
data [35].
Our study has several limitations. First, we have a
small sample size. We reported descriptive results so
that our results are interpretable within the context of
the sample, and we provided cross tables to allow
comparisons with current and future studies. Second,
we did not screen our participants with a mental
health assessment in order to decide who should be
allowed to participate in the self-reporting exercise. By
not screening participants in this way, a small number
of participants may not have been able to complete
the questionnaire accurately; however, considering the
age range of our population and features of our ques-
tionnaire designed to assist recall, we believe this to
be of little consequence in our study. Third, the
reduced research costs found when using the OCC-Q
may have been related to the small sample size. Fixed
versus variable costs differ between the analytic
approaches used in the study. Many of the databases
had larger fixed costs and smaller variable costs when
compared with the questionnaire. For example, if the
sample size increased to 150 participants, time spent
on the phone would have been unchanged for the
databases but would have nearly tripled for the ques-
tionnaire-based approach. It is possible, given a signif-
icantly larger sample size, that the research costs
would be higher for use of the OCC-Q than for the
databases. Fourth, we were unable to compare impor-
tant cost items such as patients’ work-related produc-
tivity losses, community-based allied health visits, and
informal care. These costs were collected using the
questionnaire but were unavailable from administra-
tive databases and so they were not included in the
present study.
Conclusions
The identification and valuation of health care use is a
necessary component in economic evaluations. Our
study reports on a patient-completed questionnaire that
demonstrates adequate accuracy and feasibility for cap-
turing health care use and costs, and is inexpensive
compared with obtaining this information from adminis-
trative databases. However, patient-reported co-pay-
ments may be inaccurate for some cost items.
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